{'fraction_non_alphanumeric': 0.037300177619893425, 'fraction_numerical': 0.011545293072824156, 'mean_word_length': 6.04375, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Uses of antithrombin III concentrate in congenital and acquired deficiency states

A ntithrombin 111 (AT 111) has received considerable attention as a potential therapeutic factor for both congenital and acquired deficiency states. Although its use appears to be increasing substantially, the clinical indications are unclear, because of either its lack of evaluation in controlled trials or the inexplicit long-term benefit, despite its ability to restore circulating values to “normal” levels. Herein, we review the biochemistry of p;T 111, properties of the concentrate, and its use in a variety of clinical situations including “heparin resistance,” pregnancy, disseminated intravascular coagulation (DIC), renal dysfunction, L-asparaginase (L-Ase) therapy, venoocclusive disease (VOD) of the liver, the perioperative period, liver disease, and orthotopic liver transplantation (OLT). The available data regarding the efficacy and clinical benefits of AT 111 supplementation in deficient patients are summarized, and a categorization of approved, probable, possible, and investigational indications is presented (Table 1).